LHX9

Across TCGA pan-cancer cohorts, LHX9 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated LHX9 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LHX9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LHX9 expression acts as an unfavorable survival marker.

HNSC, SCLC, and LUSC are the cancer types where LHX9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.184	0.607	.004	27	view →
SCLC	DFS	Median	II,III,IV	0.110	0.615	<.001	24	view →
LUSC	OS	Median	All	0.381	0.779	<.001	24	view →
TGCT	DFS	Median	II,III,IV	0.015	0.919	<.001	18	view →
SARC	OS	Median	All	0.032	0.861	<.001	12	view →
STAD	OS	Median	All	0.061	0.731	<.001	12	view →
LUAD	DFS	Median	III,IV	0.206	0.670	.015	6	view →
GBM	OS	Median	All	0.101	0.413	.035	3	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →
SKCM	OS	Median	All	0.145	0.328	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

LHX9–HNSC (OS)

Open the HNSC breakdown →